AcquisitionsJun 15, 2026, 09:26 AM
InterCure Closes First Tranche of Botanico Acquisition, Eyes US Market
AI Summary
InterCure Ltd. announced the successful completion of the first tranche of its acquisition of Botanico Ltd., an Israeli cannabis technology and brand company. This acquisition provides InterCure with exclusive access to award-winning American cannabis genetics, proprietary strains, premium brands, and advanced AI-driven technologies. Following the recent U.S. federal rescheduling of medical cannabis, InterCure has also initiated a strategic review of potential opportunities within regulated U.S. medical cannabis markets. The company also reported growing demand and initial revenues from the German market, with new product launches expected in H2 2026.
Key Highlights
- Completed first tranche of Botanico Ltd. acquisition, also known as ISHI.
- Issued 2,471,061 ordinary shares for the initial closing of the transaction.
- Will issue an additional 2,470,073 ordinary shares upon satisfaction of conditions.
- Gains exclusive rights to U.S. cannabis genetics, premium brands, and AI-driven technologies.
- Initiated a strategic review of opportunities in regulated U.S. medical cannabis markets.
- Reported first meaningful revenues from the rapidly growing German medical cannabis market.
- Anticipates multiple product launches in Germany in the second half of 2026.
Price Impact
More from INCR